[EN] HIV PROTEASE INHIBITING COMPOUNDS<br/>[FR] COMPOSES INHIBITEURS DE LA PROTEASE DU VIH
申请人:ABBOTT LAB
公开号:WO2005061487A1
公开(公告)日:2005-07-07
A compound of the formula (I) is disclosed as an HIV protease inhibitor. Methods and compositions for inhibiting an HIV infection are also disclosed.
公开了一种公式(I)的化合物作为HIV蛋白酶抑制剂。还公开了用于抑制HIV感染的方法和组合物。
HIV protease inhibiting compounds
申请人:Randolph T. John
公开号:US20050159469A1
公开(公告)日:2005-07-21
A compound of the formula
is disclosed as an HIV protease inhibitor. Methods and compositions for inhibiting an HIV infection are also disclosed.
公开了一种公式的化合物作为HIV蛋白酶抑制剂。还公开了用于抑制HIV感染的方法和组合物。
PROTEASE INHIBITORS HAVING ENHANCED FEATURES
申请人:Nektar Therapeutics
公开号:US20170028077A1
公开(公告)日:2017-02-02
Provided herein (among other things) are protease inhibitor compounds having enhanced features, along with methods for administering such compounds. For example, the subject compounds can be administered without concomitant administration of a CYP3A4 inhibitor, have increased therapeutic index and/or increased potency, and are low-resistance inducing in nature.
An Efficient and Practical Synthesis of the HIV Protease Inhibitor Atazanavir via a Highly Diastereoselective Reduction Approach
作者:Xing Fan、Yan-Li Song、Ya-Qiu Long
DOI:10.1021/op7001563
日期:2008.1.1
An efficient and practicalsynthesis of the HIV-1 proteaseinhibitor Atazanavir was developed by employing the diastereoselective reduction of ketomethylene aza-dipeptide isostere 10 as the key and final step. The high diastereoselectivity of the amino ketone reduction by lithium tri-tert-butoxyaluminum hydride in diethyl ether to afford the desired syn-1,2-amino alcohol structure was achieved by Felkin−Anh